Ocrelizumab 920mg/23ml solution for injection vials
NHS hospitals in England used £65,661,299 of indicative cost of Ocrelizumab 920mg/23ml solution for injection vials in the 12 months to April 2026, about 0.3% of all hospital medicines spend. That is up 200.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ocrelizumab 920mg/23ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ocrelizumab 920mg/23ml solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £8,899,820 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £6,389,860 |
| Univ Hpl B/Ham Nhs Foundation Trust | £6,083,300 |
| Western Sussex Hospitals Nhs Found Trust | £3,036,839 |
| Salford Royal Nhs Foundation Trust | £2,864,420 |
| Oxford University Hospitals Nhs Ft | £2,854,840 |
| Luton & Dunstable Hospital Trust | £2,500,380 |
| King's College Hpl Nhs Foundation Trust | £2,308,780 |
| University Hospital Southampton Nhs Ft | £2,260,880 |
| Sheffield Teaching Hospitals Nhs Trust | £2,203,400 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.